Pharmacokinetic study of aldoxorubicin in patients with solid tumors

@inproceedings{Mita2014PharmacokineticSO,
  title={Pharmacokinetic study of aldoxorubicin in patients with solid tumors},
  author={Monica M. Mita and Ronald B. Natale and Edward M. Wolin and Brenda Laabs and Hillary Dinh and Scott A. Wieland and Daniel J. Levitt and Alain C. Mita},
  booktitle={Investigational New Drugs},
  year={2014}
}
Introduction Aldoxorubicin, a prodrug of doxorubicin, binds covalently to serum albumin in the bloodstream and accumulates in tumors. Aldoxorubicin can be administered at doses several-fold higher than doxorubicin can, without associated acute cardiotoxicity. Purpose This study fully evaluated the pharmacokinetic profile of aldoxorubicin (serum and urine). Methods Eighteen patients with advanced solid tumors received aldoxorubicin 230 or 350 mg/m2 (equivalent in drug load to doxorubicin at… CONTINUE READING